Petros Grivas, MD, PhD
Ever since I was young, I’ve wanted to help other people. I knew a family friend who was a physician, and he served as a great example of how I could channel this desire, combining knowledge and compassion so that I could be of service to a community. I chose to focus on genitourinary cancers because they’re a set of very common diseases affecting the urinary tract and male reproductive system, so I felt pursuing this specialty would allow me to make a difference in the lives of many. I see this area of oncology as an opportunity to bring together my interest in innovative research and patient care.
I am dedicated to providing outstanding cancer care, which to me means taking a personalized approach with each patient and being efficient with time and resources. I hope to learn what brought you in and what your goals and expectations are — both for each visit and in the long term. While I bring a wealth of knowledge about genitourinary cancers and the latest research developments, I also believe that the little things, like a warm smile and a conversation held eye-to-eye, matter a great deal.
Specialty: Medical Oncology
I am a board-certified medical oncologist who specializes in treating patients with genitourinary cancers, such as bladder cancer and prostate cancer. My background includes leading the bladder/urothelial cancer program at the Cleveland Clinic and caring for patients at the University of Michigan, Ann Arbor. Currently, I serve as the director of UW Medicine's Genitourinary Cancers Program, giving frequent lectures, educating other oncologists and trainees and publishing novel research. I also conduct clinical trials, one of which led to the FDA approval of new drugs for bladder and urothelial cancer.
Since the COVID-19 pandemic began, oncologists have grappled with questions about potential risks and treatment changes for their cancer patients. To address these and many other questions, Seattle Cancer Care Alliance (SCCA) partnered with Fred Hutch, Vanderbilt University and other organizations to form the COVID-19 Cancer Consortium (CCC19).
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
SCCA providers are often asked to give their medical expertise for press and news publications. Read articles by or about this SCCA provider.
SCCA’s Petros Grivas, MD, spoke with OncLive about attempts to improve upon chemotherapy as a therapeutic strategy in urothelial cancer.
SCCA’s Dr. Petros Grivas moderated a webinar discussion sponsored by Cancer Network that addressed patient presentation and the major risk factors for urothelial cancer.
Your care team
SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.